GeneDx (WGS) Competitors $122.88 -0.23 (-0.19%) Closing price 04:00 PM EasternExtended Trading$122.90 +0.02 (+0.02%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock WGS vs. GH, OPCH, RDNT, BTSG, SHC, SGRY, CON, PRVA, ADUS, and PGNYShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Addus HomeCare (ADUS), and Progyny (PGNY). These companies are all part of the "healthcare" industry. GeneDx vs. Its Competitors Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group Addus HomeCare Progyny GeneDx (NASDAQ:WGS) and Guardant Health (NASDAQ:GH) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Which has better valuation and earnings, WGS or GH? GeneDx has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneDx$362.32M9.74-$52.29M$0.052,457.60Guardant Health$739.02M10.19-$436.37M-$3.35-18.02 Which has more volatility and risk, WGS or GH? GeneDx has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Do analysts recommend WGS or GH? GeneDx presently has a consensus price target of $101.63, indicating a potential downside of 17.30%. Guardant Health has a consensus price target of $57.50, indicating a potential downside of 4.74%. Given Guardant Health's stronger consensus rating and higher probable upside, analysts plainly believe Guardant Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeneDx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Guardant Health 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.06 Does the media favor WGS or GH? In the previous week, GeneDx had 7 more articles in the media than Guardant Health. MarketBeat recorded 19 mentions for GeneDx and 12 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.94 beat GeneDx's score of 0.70 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Guardant Health 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in WGS or GH? 61.7% of GeneDx shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 29.6% of GeneDx shares are owned by insiders. Comparatively, 6.1% of Guardant Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is WGS or GH more profitable? GeneDx has a net margin of 0.39% compared to Guardant Health's net margin of -49.93%. GeneDx's return on equity of 16.51% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets GeneDx0.39% 16.51% 9.35% Guardant Health -49.93%N/A -28.95% SummaryGeneDx beats Guardant Health on 9 of the 17 factors compared between the two stocks. Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.53B$7.57B$5.58B$9.81BDividend YieldN/A2.72%4.60%4.10%P/E Ratio2,457.6071.9030.2825.72Price / Sales9.7426.82388.6180.21Price / Cash113.7625.8737.7558.93Price / Book12.7318.428.456.01Net Income-$52.29M$243.10M$3.25B$265.06M7 Day Performance15.98%4.54%4.05%2.80%1 Month Performance49.14%0.47%4.32%1.68%1 Year Performance263.23%18.30%36.25%29.59% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx1.9478 of 5 stars$122.88-0.2%$101.63-17.3%+260.5%$3.53B$362.32M2,457.601,200Gap DownGHGuardant Health3.3012 of 5 stars$44.19+6.7%$54.95+24.3%+96.9%$5.17B$739.02M-13.192,021News CoverageOPCHOption Care Health4.7068 of 5 stars$28.26flat$35.75+26.5%-6.7%$4.59B$5.00B22.618,088News CoveragePositive NewsRDNTRadNet3.3111 of 5 stars$55.77+2.0%$69.60+24.8%+8.1%$4.10B$1.83B-129.6911,021News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionBTSGBrightSpring Health Services2.526 of 5 stars$19.36-1.4%$24.90+28.6%+89.1%$3.45B$11.27B62.4535,000SHCSotera Health1.2182 of 5 stars$11.28+1.2%$16.00+41.8%+5.3%$3.16B$1.10B141.023,000Earnings ReportSGRYSurgery Partners2.913 of 5 stars$22.22+4.4%$33.33+50.0%-21.5%$2.73B$3.11B-14.5215,000CONConcentra Group Holdings Parent2.1717 of 5 stars$19.79+1.6%$28.50+44.0%-0.3%$2.50B$1.90B14.7711,250News CoverageEarnings ReportDividend AnnouncementPRVAPrivia Health Group3.4221 of 5 stars$19.47+3.2%$28.38+45.8%+4.8%$2.30B$1.74B162.261,140Earnings ReportAnalyst ForecastADUSAddus HomeCare4.9441 of 5 stars$106.96+1.9%$142.57+33.3%-9.7%$1.93B$1.15B24.1449,703Positive NewsAnalyst RevisionPGNYProgyny2.1012 of 5 stars$23.18+3.1%$24.82+7.1%+6.8%$1.93B$1.17B40.67310Earnings Report Related Companies and Tools Related Companies GH Competitors OPCH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors CON Competitors PRVA Competitors ADUS Competitors PGNY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WGS) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access